Position statement on the use of albumin in liver cirrhosis
Cirrhosis is characterised by a prolonged asymptomatic period in which the inflammation persists, increasing as the disease progresses. Characteristic of this is the increase in pro-inflammatory cytokines and pro-oxidant molecules which are determining factors in the development of multiple organ dy...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-07-01
|
| Series: | Annals of Hepatology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268122000503 |
| _version_ | 1828807327301500928 |
|---|---|
| author | Graciela Castro-Narro Carlos Moctezuma-Velázquez Rene Male-Velázquez Rafael Trejo-Estrada Francisco Javier Bosques Rosalba Moreno-Alcántar Heriberto Rodríguez-Hernández Aleida Bautista-Santos Carlos Córtez-Hernández Eira Cerda-Reyes Juanita Pérez-Escobar Juan Manuel Aldana-Ledesma Jonathan Aguirre-Valadez José Antonio Velarde Ruiz-Velasco Raúl Contreras-Omaña Godolfino Miranda-Zazueta Monica del Rocío Reyes-Bastidas Javier Manuel Meza-Cardona Norberto Chávez-Tapia Nicolas Joaquín Fernández-Pérez Edgar Santino García-Jiménez Aldo Torre |
| author_facet | Graciela Castro-Narro Carlos Moctezuma-Velázquez Rene Male-Velázquez Rafael Trejo-Estrada Francisco Javier Bosques Rosalba Moreno-Alcántar Heriberto Rodríguez-Hernández Aleida Bautista-Santos Carlos Córtez-Hernández Eira Cerda-Reyes Juanita Pérez-Escobar Juan Manuel Aldana-Ledesma Jonathan Aguirre-Valadez José Antonio Velarde Ruiz-Velasco Raúl Contreras-Omaña Godolfino Miranda-Zazueta Monica del Rocío Reyes-Bastidas Javier Manuel Meza-Cardona Norberto Chávez-Tapia Nicolas Joaquín Fernández-Pérez Edgar Santino García-Jiménez Aldo Torre |
| author_sort | Graciela Castro-Narro |
| collection | DOAJ |
| description | Cirrhosis is characterised by a prolonged asymptomatic period in which the inflammation persists, increasing as the disease progresses. Characteristic of this is the increase in pro-inflammatory cytokines and pro-oxidant molecules which are determining factors in the development of multiple organ dysfunction. In the early development of cirrhosis, splanchnic arterial vasodilation, activation of vasoconstrictor systems (renin-angiotensin-aldosterone) and the sympathetic nervous system (noradrenaline) bring about bacterial translocation and systemic dissemination via portal circulation of bacterial products, and molecular patterns associated with damage, which exacerbate the systemic inflammation present in the patient with cirrhosis. Albumin is a molecule that undergoes structural and functional changes as liver damage progresses, affecting its antioxidant, immunomodulatory, oncotic and endothelial stabilising properties. Our knowledge of the properties of albumin reveals a molecule with multiple treatment options in patients with cirrhosis, from the compensated then decompensated phases to multiple organ dysfunction. Its recognised uses in spontaneous bacterial peritonitis, post-paracentesis circulatory dysfunction, acute kidney injury and hepatorenal syndrome are fully validated, and a treatment option has opened up in decompensated cirrhosis and in acute-on-chronic liver disease. |
| first_indexed | 2024-12-12T08:23:06Z |
| format | Article |
| id | doaj.art-71122652ac004bd4961dc7e338199a01 |
| institution | Directory Open Access Journal |
| issn | 1665-2681 |
| language | English |
| last_indexed | 2024-12-12T08:23:06Z |
| publishDate | 2022-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Annals of Hepatology |
| spelling | doaj.art-71122652ac004bd4961dc7e338199a012022-12-22T00:31:20ZengElsevierAnnals of Hepatology1665-26812022-07-01274100708Position statement on the use of albumin in liver cirrhosisGraciela Castro-Narro0Carlos Moctezuma-Velázquez1Rene Male-Velázquez2Rafael Trejo-Estrada3Francisco Javier Bosques4Rosalba Moreno-Alcántar5Heriberto Rodríguez-Hernández6Aleida Bautista-Santos7Carlos Córtez-Hernández8Eira Cerda-Reyes9Juanita Pérez-Escobar10Juan Manuel Aldana-Ledesma11Jonathan Aguirre-Valadez12José Antonio Velarde Ruiz-Velasco13Raúl Contreras-Omaña14Godolfino Miranda-Zazueta15Monica del Rocío Reyes-Bastidas16Javier Manuel Meza-Cardona17Norberto Chávez-Tapia18Nicolas Joaquín Fernández-Pérez19Edgar Santino García-Jiménez20Aldo Torre21Gastroenterology Department, Instituto Nacional de Ciencias Médicas y Nutrición ''Salvador Zubirán” [''Salvador Zubirán” National Institute of Medical Sciences and Nutrition], Mexico City, Mexico; Gastroenterology Unit, Hospital Médica Sur, Mexico City, MexicoGastroenterology Department, Instituto Nacional de Ciencias Médicas y Nutrición ''Salvador Zubirán” [''Salvador Zubirán” National Institute of Medical Sciences and Nutrition], Mexico City, MexicoInstituto de la Salud Digestiva y Hepática [Institute of Gastrointestinal and Liver Health], Guadalajara, Jalisco, MexicoCentro Médico ABC [ABC Medical Centre], Mexico City, MexicoHospital San José TecSalud, Monterrey, Nuevo León, MexicoCentro Médico de Alta Especialidad Siglo XXI [21st Century High Speciality Medical Centre], Mexico City, MexicoSchool of Medicine and Nutrition, Universidad Juárez del Estado de Durango, Durango, MexicoGastroenterology Department, Centro Médico Nacional 20 de Noviembre [''20 November'' National Medical Centre], Mexico City, MexicoGastroenterology Department, Hospital Universitario ''José Eleuterio González '' UANLHospital Central Militar, Mexico City, Mexico; Escuela Militar de Graduados de Sanidad, Mexico City, MexicoGastroenterology Department, Instituto Nacional de Ciencias Médicas y Nutrición ''Salvador Zubirán” [''Salvador Zubirán” National Institute of Medical Sciences and Nutrition], Mexico City, MexicoGastroenterology Department, Hospital Civil, Guadalajara, Jalisco, MexicoHospital Ángeles del Pedregal, Mexico City, MexicoGastroenterology Department, Hospital Civil de Guadalajara Fray Antonio Alcalde, Jalisco, MexicoCentro de Estudio e Investigación en Enfermedades Hepáticas y Toxicológicas (CEIHET) [Centre for Study and Research in Hepatic and Toxicological Diseases], Pachuca de Soto, Hidalgo, MexicoGastroenterology Department, Instituto Nacional de Ciencias Médicas y Nutrición ''Salvador Zubirán” [''Salvador Zubirán” National Institute of Medical Sciences and Nutrition], Mexico City, MexicoHospital Ángeles, Culiacán, Culiacán Rosales, Sinaloa, MexicoGastroenterology Department, Hospital Español de México, Mexico City, MexicoGastroenterology Unit, Hospital Médica Sur, Mexico City, MexicoHospital Ángeles León, León, Guanajuato, MexicoEscuela Militar de Graduados de Sanidad, Mexico City, MexicoMetabolic Unit, Instituto Nacional de Ciencias Médicas y Nutrición ''Salvador Zubirán” [''Salvador Zubirán” National Institute of Medical Sciences and Nutrition], Mexico City, Mexico; Corresponding author.Cirrhosis is characterised by a prolonged asymptomatic period in which the inflammation persists, increasing as the disease progresses. Characteristic of this is the increase in pro-inflammatory cytokines and pro-oxidant molecules which are determining factors in the development of multiple organ dysfunction. In the early development of cirrhosis, splanchnic arterial vasodilation, activation of vasoconstrictor systems (renin-angiotensin-aldosterone) and the sympathetic nervous system (noradrenaline) bring about bacterial translocation and systemic dissemination via portal circulation of bacterial products, and molecular patterns associated with damage, which exacerbate the systemic inflammation present in the patient with cirrhosis. Albumin is a molecule that undergoes structural and functional changes as liver damage progresses, affecting its antioxidant, immunomodulatory, oncotic and endothelial stabilising properties. Our knowledge of the properties of albumin reveals a molecule with multiple treatment options in patients with cirrhosis, from the compensated then decompensated phases to multiple organ dysfunction. Its recognised uses in spontaneous bacterial peritonitis, post-paracentesis circulatory dysfunction, acute kidney injury and hepatorenal syndrome are fully validated, and a treatment option has opened up in decompensated cirrhosis and in acute-on-chronic liver disease.http://www.sciencedirect.com/science/article/pii/S1665268122000503Liver cirrhosisAlbuminSpontaneous bacterial peritonitisHepatorenal syndromeHyponatremiaAcute-on-chronic liver failure |
| spellingShingle | Graciela Castro-Narro Carlos Moctezuma-Velázquez Rene Male-Velázquez Rafael Trejo-Estrada Francisco Javier Bosques Rosalba Moreno-Alcántar Heriberto Rodríguez-Hernández Aleida Bautista-Santos Carlos Córtez-Hernández Eira Cerda-Reyes Juanita Pérez-Escobar Juan Manuel Aldana-Ledesma Jonathan Aguirre-Valadez José Antonio Velarde Ruiz-Velasco Raúl Contreras-Omaña Godolfino Miranda-Zazueta Monica del Rocío Reyes-Bastidas Javier Manuel Meza-Cardona Norberto Chávez-Tapia Nicolas Joaquín Fernández-Pérez Edgar Santino García-Jiménez Aldo Torre Position statement on the use of albumin in liver cirrhosis Annals of Hepatology Liver cirrhosis Albumin Spontaneous bacterial peritonitis Hepatorenal syndrome Hyponatremia Acute-on-chronic liver failure |
| title | Position statement on the use of albumin in liver cirrhosis |
| title_full | Position statement on the use of albumin in liver cirrhosis |
| title_fullStr | Position statement on the use of albumin in liver cirrhosis |
| title_full_unstemmed | Position statement on the use of albumin in liver cirrhosis |
| title_short | Position statement on the use of albumin in liver cirrhosis |
| title_sort | position statement on the use of albumin in liver cirrhosis |
| topic | Liver cirrhosis Albumin Spontaneous bacterial peritonitis Hepatorenal syndrome Hyponatremia Acute-on-chronic liver failure |
| url | http://www.sciencedirect.com/science/article/pii/S1665268122000503 |
| work_keys_str_mv | AT gracielacastronarro positionstatementontheuseofalbumininlivercirrhosis AT carlosmoctezumavelazquez positionstatementontheuseofalbumininlivercirrhosis AT renemalevelazquez positionstatementontheuseofalbumininlivercirrhosis AT rafaeltrejoestrada positionstatementontheuseofalbumininlivercirrhosis AT franciscojavierbosques positionstatementontheuseofalbumininlivercirrhosis AT rosalbamorenoalcantar positionstatementontheuseofalbumininlivercirrhosis AT heribertorodriguezhernandez positionstatementontheuseofalbumininlivercirrhosis AT aleidabautistasantos positionstatementontheuseofalbumininlivercirrhosis AT carloscortezhernandez positionstatementontheuseofalbumininlivercirrhosis AT eiracerdareyes positionstatementontheuseofalbumininlivercirrhosis AT juanitaperezescobar positionstatementontheuseofalbumininlivercirrhosis AT juanmanuelaldanaledesma positionstatementontheuseofalbumininlivercirrhosis AT jonathanaguirrevaladez positionstatementontheuseofalbumininlivercirrhosis AT joseantoniovelarderuizvelasco positionstatementontheuseofalbumininlivercirrhosis AT raulcontrerasomana positionstatementontheuseofalbumininlivercirrhosis AT godolfinomirandazazueta positionstatementontheuseofalbumininlivercirrhosis AT monicadelrocioreyesbastidas positionstatementontheuseofalbumininlivercirrhosis AT javiermanuelmezacardona positionstatementontheuseofalbumininlivercirrhosis AT norbertochaveztapia positionstatementontheuseofalbumininlivercirrhosis AT nicolasjoaquinfernandezperez positionstatementontheuseofalbumininlivercirrhosis AT edgarsantinogarciajimenez positionstatementontheuseofalbumininlivercirrhosis AT aldotorre positionstatementontheuseofalbumininlivercirrhosis |